Pluvicto under the microscope: how does it perform in real life?

NCT ID NCT06514521

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 4 times

Summary

This study follows 278 men with advanced prostate cancer who are already receiving Pluvicto as part of their routine care in South Korea. Researchers will monitor side effects and how well the drug controls the cancer over time. No new treatment is given—this is purely an observation to see how Pluvicto works in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
What this could lead to: If successful, this study will confirm how safe and effective Pluvicto is in everyday clinical practice, supporting its continued use for advanced prostate cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection and real-world variability. It does not test a new treatment or compare with alternatives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Seongnam-si, Gyeonggi-do, 13620, South Korea
Novartis Investigative Site
RECRUITING

Suwon, Gyeonggi-do, 442-723, South Korea
Novartis Investigative Site
RECRUITING

Busan, Korea, 46033, South Korea
Novartis Investigative Site
RECRUITING

Gyeonggi-do, Korea, 10408, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Seoul, 03374, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Seoul, 06351, South Korea
Novartis Investigative Site
RECRUITING

Jeollanam, 519763, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 01812, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03722, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 05505, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 06591, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 110-744, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.